Despite recent advances in the treatment of CKD, neither renin-angiotensin system blockade nor sodium–glucose cotransporter-2 inhibitors (SGLT-2i), the current standard of therapy for diabetic and non-diabetic CKD, have been shown to restore the risk of kidney failure and premature death to baseline in any group of age and sex [10]. The gene discussed is REN; the disease is chronic kidney disease.